Immunogenicity of the inactivated influenza vaccine in children who have undergone autologous stem cell transplant
CORRESPONDENCE To the Editor: Autologous stem cell transplant (SCT) is an upfront therapeutic modality for children with malignancies such as high-risk neuroblastoma and atypical teratoid rhabdoid tumour and a salvage option for children with lymphoma and a variety of solid tumours. The admini...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
2019
|
| Online Access: | http://purl.org/au-research/grants/nhmrc/1142627 http://hdl.handle.net/20.500.11937/80804 |
| Summary: | CORRESPONDENCE
To the Editor: Autologous stem cell transplant (SCT) is an upfront therapeutic modality for children with malignancies such as
high-risk neuroblastoma and atypical teratoid rhabdoid
tumour and a salvage option for children with lymphoma
and a variety of solid tumours. The administration of highdose myeloablative chemotherapy during conditioning
increases vulnerability to infection. Influenza infection can
result in significant complications, in particular progression
to pneumonia, in patients who have undergone autologous
SCT [1, 2]. Influenza vaccination is recommended to prevent
infection in children following autologous SCT [3], however, there is limited evidence regarding its benefit in this
population [4]. Due to the paucity of data, we performed a
prospective multicentre study to evaluate the immunogenicity of the seasonal inactivated influenza vaccine in children
who have undergone autologous SCT compared with healthy matched controls. |
|---|